Cirurgia de Esôfago

Diretrizes SAGES para o tratamento cirúrgico do refluxo gastresofágico.

21 Jul, 2021 | 09:50h

SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD) – Surgical Endoscopy

---

Impacto global do câncer atribuído ao consumo de álcool – “Em termos globais, estima-se que 741.300 casos, ou 4,1% de todos os novos casos de câncer em 2020, foram atribuídos ao consumo de álcool.”

14 Jul, 2021 | 11:36h

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study – The Lancet Oncology

Comunicado de imprensa: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet

Comentários: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian E Expert reaction to study of alcohol and cancer – Science Media Centre

---

Estudo randomizado | Eficácia de longo prazo da quimiorradioterapia neoadjuvante somada à cirurgia para o tratamento de carcinoma esofágico de células escamosas localmente avançado.

13 Jul, 2021 | 11:09h

Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC₅₀10 Randomized Clinical Trial – JAMA Surgery

Comentário: Neoadjuvant chemoradiotherapy plus surgery increases overall survival of patients with advanced esophageal squamous cell carcinoma compared to surgery alone – 2 Minute Medicine

 

Comentário no Twitter

Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy

— JAMA Surgery (@JAMASurgery) June 29, 2021

 

---

Ranitidina absolvida? Estudo do FDA mostra que a ranitidina não é convertida ao carcinógeno NDMA, independentemente da dieta.

12 Jul, 2021 | 11:23h

Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial – JAMA

Editorial: Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation

Comentário: Ranitidine: FDA finds no evidence of elevated NDMA, regardless of diet

 

Comentário no Twitter

Despite ranitidine (zantac) being pulled from market last year, a new study from the FDA did not find evidence that it increases concentrations of the carcinogenic metabolite people were worried about (i.e., it's probably safe). From @JAMA_current https://t.co/AdRic2GdXS

— Zack Williams (@QuantPsychiatry) June 28, 2021

In this crossover, randomized clinical trial, oral ranitidine did not significantly increase 24-hour urinary excretion of NDMA when administered with a noncured-meats diet or a cured-meats diet. https://t.co/EszRvfJOFJ

— JAMA (@JAMA_current) June 28, 2021

 

---

Estudo randomizado: Quimioterapia de intensidade reduzida em pacientes idosos frágeis com câncer gastresofágico avançado propicia uma melhor experiência ao paciente, sem perda significativa no controle da doença.

20 Mai, 2021 | 10:42h

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial – JAMA Oncology

Comentário: Lowering Chemo Dose Achieved Happier Patients, Good Outcomes in Elderly GI Cancer Patients – Physician’s Weekly

 

Comentário no Twitter

The GO2 trial tested reduced intensity of chemo for pts w adv gastroesophageal cancer & found reducing intensity led to comparable survival but w improved patient experience, & decision-making can be enhanced using geriatric assessment https://t.co/DtZOXcozo7 #GeriOnc

— JAMA Oncology (@JAMAOnc) May 13, 2021

 

---

Resultados de longo prazo em estudo randomizado confirmam os benefícios da quimiorradioterapia neoadjuvante somada à cirurgia para câncer esofágico.

20 Mai, 2021 | 10:41h

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial – Journal of Clinical Oncology

 

Comentários no Twitter

Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer

☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe

— Gil Morgan (@weoncologists) May 14, 2021

Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB

— ASCO Publications (@ASCO_pubs) May 5, 2021

 

---

Estudo randomizado: Entre pacientes com câncer esofágico, anastomose intratorácica após esofagectomia total ou híbrida minimamente invasiva resultou em menores taxas de vazamento anastomótico e melhores desfechos quando comparada com anastomose cervical.

18 Mai, 2021 | 10:38h

Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial – JAMA Surgery (gratuito por tempo limitado)

Comentário convidado: Does the Location Matter for the Anastomosis for Minimally Invasive Esophagectomy? (gratuito por tempo limitado)

 

Comentário no Twitter

Intrathoracic anastomosis after MIE is associated with a lower anastomotic leakage rate and better outcome for patients with mid to distal esophageal or gastro-esophageal junction cancer: results of the ICAN trial https://t.co/CXv2CeCnuX pic.twitter.com/QCYg4UJeyF

— JAMA Surgery (@JAMASurgery) May 12, 2021

 

---